<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367756</url>
  </required_header>
  <id_info>
    <org_study_id>BP25679</org_study_id>
    <nct_id>NCT01367756</nct_id>
  </id_info>
  <brief_title>A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Double-blind, Parallel-design Study to Investigate the Safety and Tolerability of RO4995819 in Combination With Citalopram Following Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, parallel-arm study will assess the safety and tolerability of
      RO4995819 in combination with citalopram in healthy volunteers. Subjects will receive
      citalopram orally on Days 1-9 and be randomized to receive either RO4995819 orally or placebo
      in combination with citalopram on Days 10-16. Safety follow-up will be up to Day 58.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>up to 58 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of multiple doses of RO4995819 on the pharmacokinetics (Cmax, AUC) of citalopram</measure>
    <time_frame>17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of genetic variants of drug metabolism on pharmacokinetics (Cmax, AUC) of RO4995819 in combination with citalopram</measure>
    <time_frame>up to 58 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4995819</intervention_name>
    <description>multiple oral doses, Days 10-16</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>multiple oral doses, Days 1-16</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>multiple oral doses, Days 10-16</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy male or female subjects, 18 to 65 years of age inclusive (healthy status
             defined as absence of evidence of any active or chronic disease)

          -  Body mass index (BMI) 18.0 to 30.0 kg/m2 inclusive

          -  Female subjects who are not either surgically sterile or post-menopausal must commit
             to using a barrier form of contraception in addition to either an intrauterine device
             or hormonal contraception until at least 5 months after the last dose of study drug

          -  Male subjects must use a barrier method of contraception throughout the study and for
             up to 5 months after the last dose of study drug (applies also to surgically
             sterilized males)

          -  Willing not to participate in any other clinical trial with an investigational drug
             for at least 5 months following the last dose of study drug

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Suspicion of regular consumption of drug of abuse or positive test for alcohol on Day
             -2

          -  Hepatitis B, hepatitis C or HIV infection

          -  Smokers of &gt;5 cigarettes or equivalent tobacco intake per day

          -  Any confirmed allergic reaction against any drug, or multiple allergies (non-active
             hay fever is acceptable)

          -  Participation in an investigational drug or device study within 3 months prior to
             dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

